Related Experiment Video

Updated: Feb 14, 2026

Orthotopic Mouse Model of Colorectal Cancer
08:43

Orthotopic Mouse Model of Colorectal Cancer

Published on: December 4, 2007

47.3K

MiR-27b directly targets Rab3D to inhibit the malignant phenotype in colorectal cancer

Yang Luo1, Shi-Yong Yu2, Jian-Jun Chen1

  • 1Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, P.R. China.

Oncotarget
|February 10, 2018
PubMed

Insights

MicroRNA-27b (miR-27b) is down-regulated in colorectal cancer, suppressing tumor growth and invasion by targeting Rab3D. This suggests miR-27b is a potential biomarker and therapeutic target for colorectal cancer.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • MicroRNAs (miRNAs) regulate gene expression post-transcriptionally.
  • Their roles as oncogenes or tumor suppressors are critical in colorectal cancer (CRC).
  • The specific function of miR-27b in CRC is largely unknown.

Purpose of the Study:

  • To investigate the role of miR-27b in colorectal cancer.
  • To identify miR-27b's target gene(s) and their involvement in CRC progression.
  • To evaluate miR-27b as a potential prognostic biomarker and therapeutic target for CRC.

Main Methods:

  • Analysis of miR-27b expression in colorectal cancer tissues.
  • Gain- and loss-of-function studies to assess miR-27b's effects on cell proliferation and invasion.
  • Luciferase reporter assays to identify direct targets.
  • In vivo animal experiments to validate findings.

Main Results:

  • miR-27b was significantly down-regulated in colorectal cancer tissues.
  • Lower miR-27b expression correlated with shorter patient survival.
  • miR-27b suppressed colorectal cancer cell proliferation and invasion.
  • Rab3D was identified as a direct functional target of miR-27b.
  • Rab3D partially reversed the anti-proliferative and anti-invasive effects of miR-27b.
  • Animal studies confirmed miR-27b's role in inhibiting CRC progression via Rab3D.

Conclusions:

  • miR-27b inhibits colorectal cancer cell growth and invasion by targeting Rab3D.
  • miR-27b functions as a tumor suppressor in colorectal cancer.
  • miR-27b holds potential as a prognostic biomarker and therapeutic target for colorectal cancer.
Keywords:
Rab3Dcolorectal cancermiR-27bprognosis

More Related Videos

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer06:01

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer

Published on: July 6, 2017

10.0K
Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

7.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.4K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
5
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
Background and Environment Affect Phenotype02:27

Background and Environment Affect Phenotype

Although the genetic makeup of an organism plays a major role in determining the phenotype, there are also several environmental factors, such as temperature, oxygen availability, presence of mutagens, that can alter an organism’s phenotype.
An example of how genetic background affects phenotype can be seen in horses. The Extension gene in horses is responsible for their coat color. A wild-type gene (EE) produces black pigment in the coat, while a mutant gene (ee) produces red pigment. A...
7.8K